Cagrilintide

Purogiramu inonzi Cagrilintide

Cagrilintideinogara kwenguva refu, yakagadzirwa nemakemikariamylin receptor agonist, yakagadzirwa semushonga mutsva wekufutisa uye uremu zvine chekuita nekusagadzikana kwemetabolism. Yakagadzirirwa kutevedzera maitiro eamylin yevanhu, hormone yakabatanidzwa ne insulin nepancreatic β-cells, iyo inoita basa rinokosha mukugadzirisa kudya, kubuda kwegastric, uye satiety.

Cagrilintide iri kugadzirwa seakamwe-vhiki nevhiki jekiseni kurapwa, kupa mhinduro inovimbisa zvikuru yechronic weight management, kunyanya kana inoshandiswa mukatikusanganiswa neGLP-1 receptor agonistszvakaita seSemaglutide.

Nzira Yekuita

Cagrilintide inoshandisa maitiro ayo ekurapa nekusunga uye kuitaamylin receptors, zvinotungamira ku:

• Kudzvinyirirwa kwekudya

• Kunonoka kubuda mudumbu, izvo zvinorebesa kunzwa kwekuzara

• Yakaderedzwa calorie kudya uye kuwedzera satiety

Iyi multimodal regulation yekudya kwekudya inoita kuti ive yakakodzera mumiriri wekutongakufutisa uye zvine chekuita ne cardiometabolic njodzi.

Tsvagiridzo uye Clinical Data

Cagrilintide yakaratidza mhedzisiro inovimbisa mune akati wandei miedzo yekiriniki, kusanganisiraChikamu chechipiri zvidzidzo zvakaitwa naNovo Nordisk:

• Kana yashandiswandega, Cagrilintide inotungamira kunedose-inotsamira uremu kurasikirwa, pamwe kusvika10.8% kuderedza uremu hwemuvirikwemavhiki e26 muvanhu vakafuta.

• Riniyakasanganiswa neSemaglutide, mhedzisiro yekurasikirwa kwehuremu inowedzerwa zvakanyanya-kuitakuderera kukuru kwehuremu hwemuviri kupfuura chero mumiririri wega.

• Zvaratidzayakanaka tolerabilityuyechimiro chekuchengetedza chakasimba, nezviitiko zvakanyanya kuipa zviri zvinyoro zviratidzo zvedumbu.

Iyi nzira yekusanganiswa ndiyo chikamu chakakosha cheiyochizvarwa chinotevera anti-obesity drug pipeline, kunanga nzira dzakawanda dzekuguta (amylin + GLP-1).

API Hunhu uye Kugadzira

YeduPurogiramu inonzi Cagrilintide:

• Inogadzirwa neAdvancedsolid-phase peptide synthesis (SPPS)nekuchena kwepamusoro uye kugadzikana kwemakemikari

• Yakagadzirirwainjectable formulation development

• Inosangana nedzimwe nyikamishonga mitemo (ICH, GMP, FDA)

• Inowanikwa mupilot kune zvekutengesa-scale kugadzirwa, yakakodzera kuchipatara uye kushandiswa kwemaindasitiri

Therapeutic Potential

Cagrilintide inomiririra anovel mechanismmukutonga uremu kupfuura GLP-1 monotherapy. Yayo inopindirana chiitiko chimiro inoita kuti ive yakakodzera kune:

• Obesity uye varwere vakafuta(ane kana asina chirwere cheshuga)

• Combination therapykuti uwedzere kuonda

• Future development inmetabolic syndrome uye prediabetes